摘要
目的:探讨乳腺癌患者新辅助化疗的药学监护模式。方法:对1例炎性乳腺癌患者进行药学监护。患者开始选用多西他赛+卡铂+曲妥珠单抗(TCH)的治疗方案;病情进展后,考虑TCH治疗方案中紫杉醇类可能发生耐药,将治疗方案换成长春瑞滨+顺铂+曲妥珠单抗(NPH)。结果与结论:临床药师可从合理选药、规范给药、患者教育及用药信息咨询三大方面对乳腺癌患者进行药学监护,从个体化用药角度出发,进一步完善药学监护模式,从而提高乳腺癌患者的药物治疗效果。
OBJECTIVE： To investigate the pharmaceutical care mode of neoadjuvant chemotherapy for breast cancer patients. METHODS： Clinical pharmacists provided pharmaceutical care for a patient with inflammatory breast cancer. The patient received docetaxel＋carboplatin＋trastuzumab （TCH） ; and then received vinorelbine＋carboplatin＋trastuzumab （NPH） instead due to drug re sistance to paclitaxel. RESULTS＆CONCLUSIONS： Clinical pharmacists can provide pharmaceutical care for breast cancer patient through rational choice of drugs, standardized medication, patient education and medication information consultant. From the angle of rational individual use of drugs, the mode of pharmaceutical care should be improved to enhance effacacy of drug therapy for breast cance patients.
出处
《中国药房》
CAS
CSCD
2014年第6期563-565,共3页
China Pharmacy
关键词
乳腺癌
药学监护
新辅助化疗
Breast cancer
Pharmaceutical care
Neoadjuvant chemotherapy
